Saturday 17 October 2026
Export INKT’s income statement to Excel — free account
MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.5% and free cash flow fell 32.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.41
0.53
−5.33%
Follow INKT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
79.54% | 73.90% | 72.34% | 57.94% | |
| (110.62%) | (125.20%) | (170.31%) | (187.78%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(807.54%) | (1,034.81%) | (403.61%) | (555.09%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.26) | (1.39) | (1.32) | (1.36) | |
Free Cash Flow |
(5.58) | (5.93) | (6.32) | (6.83) | |
| Other line items | |||||
Cash ROIC |
(726.26%) | 683.10% | 199.88% | 130.82% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.45 | 0.47 | 0.51 | 0.60 | |
Depreciation/Fixed assets |
0.46 | 0.46 | 0.47 | 0.48 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.26) | (1.39) | (1.32) | (1.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates